Aerovate Therapeutics Company

Aerovate Therapeutics is a biotechnology company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's program is a potentially disease-modifying drug, AV-101, for people who suffer from pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of the drug imatinib that delivers this medicine directly to diseased lung tissues while reducing systemic adverse side effects. The company was founded and incubated by RA Capital Management, a multi-stage investment manager focused on healthcare and life sciences.

Last Funding Type: Series A
Funding Status: IPO
Headquarters: Boston, Massachusetts, United States
Founded Date: 2019-01-01
Total Funding: 72600000
Technology: Anti-infective Drugs
Employee Number: 1-10
Industry: BioTech